Plan a coordinated lung and kidney safety study using organ-specific injury evidence, identity QC and readouts tailored to one candidate program.
STUDY EVIDENCE
Normal-lung studies connect alveolar- and airway-associated phenotypes with an LPS injury comparison, while kidney organoid studies combine identity profiling with serial morphology after doxorubicin exposure. New candidate studies can match model provenance, exposure conditions and assay endpoints to each organ.
Bright-field, DAPI, LysoTracker and merged views show alveolar organoid morphology and ATII-associated acidic-organelle signal.
Supports selection of alveolar-associated phenotype and injury endpoints
Immunofluorescence shows club- and basal-cell profiles that help distinguish alveolar- and airway-focused study directions.
Helps determine whether alveolar- or airway-focused endpoints are more relevant to the candidate
Bright-field views on days 1, 5 and 7 guide post-treatment observation timing and follow-on quantitative endpoints.
Supports selection of the observation window for pulmonary-injury studies
Bright-field, AT1, AT2, DAPI and merged views connect the injury condition with alveolar-cell profiling.
Supports selection of alveolar-cell injury endpoints
Bright-field and inset views provide structural context for subsequent identity and injury assays.
Supports selection of nephron identity assays
Nephrin- and LTL-associated signals provide podocyte- and tubule-related context for selecting cell-type-relevant endpoints.
Supports selection of organ- and cell-type-relevant safety endpoints
Bright-field imaging before exposure and at 24/48 hours shows the time course of morphological change and guides downstream sampling and assay timing, including alignment of the kidney observation window in a two-organ study.
Supports selection of kidney-injury observation and sampling timesINTERPRETATION
Select a lung, kidney or dual-organ strategy with safety endpoints matched to the candidate's risk profile.
The lung and kidney studies provide organ-specific model identity, injury endpoints and observation windows. For the same candidate, our scientists can design complementary studies with dose, timing and controls tailored to each organ, helping your team assess risk signals across organs.
Set exposure gradients and recovery studies around the candidate mechanism, with organ-specific molecular endpoints and batch replication.
Related models and services
PROJECT DISCUSSION
Share your project goal and available materials. Our scientists will recommend models, controls, assays and a practical first study.
Plan a coordinated lung and kidney safety study using organ-specific injury evidence, identity QC and readouts tailored to one candidate program.
STUDY EVIDENCE
Normal-lung studies connect alveolar- and airway-associated phenotypes with an LPS injury comparison, while kidney organoid studies combine identity profiling with serial morphology after doxorubicin exposure. New candidate studies can match model provenance, exposure conditions and assay endpoints to each organ.
Bright-field, DAPI, LysoTracker and merged views show alveolar organoid morphology and ATII-associated acidic-organelle signal.
Supports selection of alveolar-associated phenotype and injury endpointsImmunofluorescence shows club- and basal-cell profiles that help distinguish alveolar- and airway-focused study directions.
Helps determine whether alveolar- or airway-focused endpoints are more relevant to the candidateBright-field views on days 1, 5 and 7 guide post-treatment observation timing and follow-on quantitative endpoints.
Supports selection of the observation window for pulmonary-injury studiesBright-field, AT1, AT2, DAPI and merged views connect the injury condition with alveolar-cell profiling.
Supports selection of alveolar-cell injury endpointsBright-field and inset views provide structural context for subsequent identity and injury assays.
Supports selection of nephron identity assaysNephrin- and LTL-associated signals provide podocyte- and tubule-related context for selecting cell-type-relevant endpoints.
Supports selection of organ- and cell-type-relevant safety endpointsBright-field imaging before exposure and at 24/48 hours shows the time course of morphological change and guides downstream sampling and assay timing, including alignment of the kidney observation window in a two-organ study.
Supports selection of kidney-injury observation and sampling timesINTERPRETATION
Select a lung, kidney or dual-organ strategy with safety endpoints matched to the candidate's risk profile.
The lung and kidney studies provide organ-specific model identity, injury endpoints and observation windows. For the same candidate, our scientists can design complementary studies with dose, timing and controls tailored to each organ, helping your team assess risk signals across organs.
Set exposure gradients and recovery studies around the candidate mechanism, with organ-specific molecular endpoints and batch replication.
Related models and services
PROJECT DISCUSSION
Share your project goal and available materials. Our scientists will recommend models, controls, assays and a practical first study.
